Advances in mRNA & LNP technology for in vivo CAR‑T therapy
About this webinar
In vivo CAR-T therapy requires durable, yet transient CAR expression coupled with efficient, T cell-specific delivery. This webinar will focus on how innovations in RNA design and next-generation lipid nanoparticle (LNP) technology are enabling direct in vivo engineering of T cells, replacing conventional ex vivo manufacturing. This webinar will explore key advances in CAR construct design and novel LNP formulations to improve the precision, potency and safety of in vivo CAR-T therapies.
Modular “drop-in” CAR plasmids that streamline both construct design and RNA production will be introduced. These vectors produce mRNAs optimized for CAR expression and support flexible swapping of antigen-binding domains, enabling rapid screening and efficient customization. This approach may be particularly useful for researchers who are new to CAR-T development.
The featured speaker will present recent innovations in RNA design to enhance expression, durability and tissue specificity. These innovations include a modified poly(A) tail that improves transcript stability and translational efficiency and a T cell-specific internal ribosome entry site (IRES) that, when incorporated into circular RNA (circRNA), restricts CAR expression to T cells and reduces off-target effects.
This session will also highlight novel LNP technology engineered for T cell-directed delivery, including exosome-like and spleen-tropic LNPs that enrich delivery to lymphoid tissues where T cells are concentrated and improve CAR expression. VHH site-specific conjugated LNPs that employ single-domain antibody fragments for precise T cell targeting will also be discussed. Collectively, these advances in CAR construct design, RNA engineering and targeted LNP systems represent a comprehensive toolbox for next-generation in vivo CAR-T therapy development.
Register for this webinar to learn how LNP technology can support targeted RNA delivery and in vivo CAR-T cell engineering.
Who should attend
- Novice and advanced CAR-T therapy development
- mRNA and circRNA design
- LNP formulation and targeted LNP development
- Non-viral delivery
What you will learn
- Gain an understanding of the concepts of CAR-T therapy and how LNP delivery of mRNA can be used for in vivo CAR-T cell engineering
- Discover how recent innovations in mRNA design and LNP formulations enable in vivo CAR-T development
- Learn how to apply the latest in in vivo CAR-T technology to research and clinical programs
Featured Speakers
Mark Shulewitz, PhD
Dr. Mark Shulewitz received his PhD in Molecular and Cell Biology from U.C. Berkeley. He has worked as an Individual Contributor and R&D Manager in the Biotechnology and Life Science Industries. His extensive experience ranges from basic cancer research to drug discovery to the development and commercialization of products for life science research. As a Field Application Scientist at GenScript, he is dedicated to supporting the Life Science research community in making groundbreaking discoveries and developing the next generation of therapeutics.
Partner for this event
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to make people and nature healthier through biotechnology by scripting possibilities.